Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Supplementary Prognostic Variables For Pleural Mesothelioma

H. Pass, D. Giroux, Catherine Kennedy, E. Ruffini, A. K. Cangir, D. Rice, H. Asamura, D. Waller, John Edwards, W. Weder, H. Hoffmann, J. Van Meerbeeck, V. Rusch
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Introduction: The staging system for malignant pleural mesothelioma is controversial. To revise this system, the International Association for the Study of Lung Cancer Staging Committee developed an international database. This report analyzes prognostic variables in a surgical population, which are supplementary to previously published CORE variables (stage, histology, sex, age, and type of procedure). Methods: Supplementary prognostic variables were studied in three scenarios: (1) all data available, that is, patient pathologically staged and other CORE variables available (2) only clinical staging available along with CORE variables, and (3) only age, sex, histology, and laboratory parameters are known. Survival was analyzed by Kaplan–Meier, prognostic factors by log rank and stepwise Cox regression modeling after elimination of nonsignificant variables. p value less than 0.05 was significant. Results: A total of 2141 patients with best tumor, node, metastasis (TNM) stages (pathologic with/without clinical staging) had nonmissing age, sex, histology, and type of surgical procedure. Three prognostic models were defined. Scenario A (all parameters): best pathologic stage, histology, sex, age, type of surgery, adjuvant treatment, white blood cell count (WBC) (≥15.5 or not), and platelets (≥400 k or not) (n = 550). Scenario B (no surgical staging): clinical stage, histology, sex, age, type of surgery, adjuvant treatment, WBC, hemoglobin (<14.6 or not), and platelets (n = 627). Scenario C (limited data): histology, sex, age, WBC, hemoglobin, and platelets (n = 906). Conclusion: Refinement of these models could define not only the appropriate patient preoperatively for best outcomes after cytoreductive surgery but also stratify surgically treated patients after clinical and pathologic staging who do or do not receive adjuvant therapy.
This paper references
10.1016/j.jtcvs.2012.09.023
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
M. Baud (2013)
10.1016/j.athoracsur.2009.01.026
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1016/j.ejca.2009.04.028
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
J. Francart (2009)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.1158/1078-0432.CCR-10-2245
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
S. Kao (2010)
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.1016/j.jtcvs.2013.01.039
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
V. Rusch (2013)
10.1097/JTO.0b013e31822a3740
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
hsa - miR - 29 c * is linked to the prognosis of malignant pleural mesothelioma
HI Pass (2010)
10.1510/icvts.2010.255901
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1093/jnci/djp061
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
10.1093/jjco/hyq159
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
S. Nojiri (2011)
10.3978/j.issn.2225-319X.2012.10.04
Biomarkers and prognostic factors for mesothelioma.
H. Pass (2012)
10.1016/j.cllc.2012.03.011
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
10.1007/S00420-003-0498-6
Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register
V. Neumann (2004)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1158/0008-5472.CAN-09-3993
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
H. Pass (2010)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)



This paper is referenced by
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
10.1093/jjco/hyv039
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Yuki Kataoka (2015)
10.1080/15384047.2018.1449614
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
N. Nicolaides (2018)
10.1007/s00268-017-4264-4
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
W. Vigneswaran (2017)
10.1080/10937404.2016.1195321
Investigating palygorskite’s role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity
D. Larson (2016)
10.2217/LMT.15.32
New directions in mesothelioma treatment
Anna K. Nowak (2015)
10.1016/j.athoracsur.2016.08.063
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
W. Vigneswaran (2017)
10.1016/S2213-2600(19)30139-0
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
G. Scagliotti (2019)
10.21037/jtd.2017.12.139
Malignant pleural mesothelioma-the impact of globalization on rare diseases.
M. A. Hoda (2018)
10.1016/j.lungcan.2018.01.001
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Juuso Paajanen (2018)
10.1186/s13550-020-00669-3
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
M. Pavic (2020)
10.1016/j.jtho.2016.02.006
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma
H. Pass (2016)
10.21037/jtd.2016.07.55
Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.
A. Sandri (2016)
10.1097/MNM.0000000000000402
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma
O. Ozmen (2016)
10.1007/978-3-319-28761-4_21
Modern Surgical Techniques in Malignant Pleural Mesothelioma
Y. Kahya (2016)
10.3978/j.issn.2072-1439.2015.11.15
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
T. Tagawa (2015)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1016/j.jtcvs.2019.08.027
Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
F. Lococo (2019)
10.21103/5(1)_cr1
Prognostic Factors in Patients with Malignant Pleural Mesothelioma
Aleksey N. Kurchenkov (2015)
10.1016/j.jtcvs.2014.10.109
Povidone iodine: the new solution for mesothelioma?
V. Rusch (2015)
10.21037/shc.2018.06.06
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
10.1016/j.lungcan.2016.07.023
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
A. Sharkey (2016)
10.1016/j.ejrad.2016.11.019
Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
K. Kitajima (2017)
10.21037/tlcr.2018.06.07
Extended pleurectomy decortication: the current role.
R. Bilancia (2018)
10.1093/ejcts/ezv403
The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.
A. Sharkey (2016)
10.1016/j.soc.2020.06.002
Updates in Staging and Management of Malignant Pleural Mesothelioma.
A. Wolf (2020)
10.5301/tj.5000364
Sarcomatoid Mesothelioma: Future Advances in Diagnosis, Biomolecular Assessment, and Therapeutic Options in a Poor-Outcome Disease
D. Galetta (2016)
10.5772/intechopen.91769
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1016/j.jtho.2015.10.003
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
A. Billè (2016)
10.1093/icvts/ivx221
Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.
A. Sharkey (2017)
10.1053/j.jvca.2020.07.017
The 2019 ERS/ESTS/EACTS/ESTRO Guidelines on the Management of Patients With Malignant Pleural Mesothelioma.
T. Gelzinis (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar